Therapy of Myasthenia Gravis and Myasthenic Syndromes

Neurological Disorders: Course and Treatment: Second Edition

Volumn , Issue , 2003, Pages 1341-1362

  Hohlfeld, Reinhard ^a   Melms, A ^b   Schneider, C ^c   Toyka, K V ^d   Drachman, D B ^e  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0042815705     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012125831-3/50289-6     Document Type: Chapter

References (104)

1. Achiron A., Barak Y., Miron S., Sarova-Pinhas I. Immunoglobulin treatment in refractory myasthenia gravis. Muscle Nerve 2000, 23:551-555.
2. Adams C., Theodorescu D., Murphy E.G., Shandling B. Thymectomy in juvenile myasthenia gravis. J. Child. Neurol. 1990, 5:215-218.
3. Andrews P.I. A treatment algorithm for autoimmune myasthenia gravis in childhood. Ann. N Y Acad. Sci. 1998, 841:789-802.
4. Arsura E., Brunner N.G., Namba T., Grob D. High-dose intravenous methylprednisolone in myasthenia gravis. Arch. Neurol. 1985, 42:1149-1153.
5. Bain P.G., Motomura M., Newsom-Davis J., Misbah S.A., Chapel H.M., Lee M.L., Vincent A., Lang B. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996, 47:678-683.
6. Bassan H., Muhlbaur B., Tomer A., Spirer Z. High-dose intravenous immunoglobulin in transient neonatal myasthenia gravis. Pediatr. Neurol. 1998, 18:181-183.
7. Bassan H., Spirer Z. Intravenous immunoglobulin in neonatal myasthenia gravis. J. Pediatr. 1999, 135:790.
8. Batocchi A.P., Majolini L., Evoli A., Lino M.M., Minisci C., Tonali P. Course and treatment of myasthenia gravis during pregnancy. Neurology 1999, 52:447-452.
9. Beeson D., Jacobson L., Newsom-Davis J., Vincent A. A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis. Neurology 1996, 47:1552-1555.
10. Benny W.B., Sutton D.M., Oger J., Bril V., McAteer M.J., Rock G. Clinical evaluation of a staphylococcal protein A immunoadsorption system in the treatment of myasthenia gravis patients. Transfusion 1999, 39:682-687.
11. Besinger U.A., Toyka K.V., Heininger K., Fateh-Moghadam A., Schumm F., Sandel P.C., Birnberger K.L. Long term correlation of clinical course and acetylcholine receptor antibody in patients with myasthenia gravis. Ann. N Y Acad. Sci. 1981, 377:812-813.
12. Blaes F., Beeson D., Plested P., Lang B., Vincent A. IgG from "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not human acetylcholine receptor. Ann. Neurol. 2000, 47:504-510.
13. Bonifati D.M., Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J. Neurol. 1997, 244:542-547.
14. Bromberg M.B., Wald J.J., Feldman E.L., Albers J.W. Randomized trial of azathioprine or predisone for initial immunosuppressive treatment of myasthenia gravis. J. Neurol. Sci. 1997, 150:59-62.
15. Buckingham J.M., Howard F.M., Bernatz P.E., Payne W.S., Harrison E.G., O'Brien P.C., Weiland L.H. The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Ann. Surg. 1976, 184:453-458.
16. Bufler J., Kahlert S., Tzartos S., Toyka K.V., Maelicke A., Franke C. Activation and blockade of mouse muscle nicotinic channels by antibodies directed against the binding site of the acetylcholine receptor. J. Physiol. 1996, 492(Pt 1):107-114.
17. Chaudhry V.V., Cornblath D.R., Griffin J.W., O'Brien R., Drachman D.B. Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001, 56:94-96.
18. Ciafaloni E., Massey J.M., Tucker-Lipscomb B., Sanders D.B. Mycophenolate mofetil for myasthenia gravis: An openlabel pilot study. Neurology 2001, 56:97-99.
19. Ciafaloni E., Nikkar N.K., Massey J.M., Sanders D.B. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000, 55:448-450.
20. Compston D.A.S., Vincent A., Newsom-Davis J., Batchelor J.R. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980, 103:579-601.
21. Cornelio F., Antozzi C., Confalonieri P., Baggi F., Mantegazza R. Plasma treatment in diseases of the neuromuscular junction. Ann. N Y Acad. Sci. 1998, 841:803-810.
22. Cowen D., Hannoun-Levi J.M., Resbeut M., Alzieu C. Natural history and treatment of malignant thymoma. Oncology (Huntingt.) 1998, 12:1001-1005.
23. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 1994, 330:1797-1810.
24. Dudel J., Birnberger K.L., Toyka K.V., Schlegel C., Besinger U. Effects of myasthenic immunoglobulins and of prednisolone on spontaneous miniature end-plate potentials in mouse diaphragms. Exp. Neurol. 1979, 66:365-380.
25. Dwyer J.M. Manipulating the immune system with immune globulin. N. Engl. J. Med. 1992, 326:107-116.
26. Edan G., Landgraf F. Experience with intravenous immunoglobulin in myasthenia gravis: a review. J. Neurol. Neurosurg. Psychiatry 1994, 57(Suppl):55-56.
27. Elion G.B. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann. N Y Acad. Sci. 1993, 685:400-407.
28. Ellis R.J., Swendson M.R., Bajorek J. Aseptic meningitis as a complication of intravenous immunoglobulin therapy for myasthenia gravis. Muscle Nerve 1994, 17:683-684.
29. Engel A.G., Ohno K., Sine S.M. Congenital myasthenic syndromes. Myasthenia Gravis and Myasthenic Disorders 1999, 251-297. Oxford University Press, Oxford, UK. A.G. Engel (Ed.).
30. Flachenecker P., Taleghani B.M., Gold R., Grossmann R., Wiebecke D., Toyka K.V. Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide. Transfus. Sci. 1998, 19(Suppl):43-46.
31. Gajdos R., Chevret S., Clair B., Tranchant C., Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann. Neurol. 1997, 41:789-796.
32. Gajdos P., Chevret S., Clair B., Transchant C., Chastang C. Plasma exchange and intravenous immunoglobulin in autoimmune myasthenia gravis. Ann. N Y Acad. Sci. 1998, 841:720-726.
33. Genkins G., Kornfeld P., Qsserman K.E., Namba T., Grob D., Brunner N.G. The use of ACTH and corticosteroids in myasthenia gravis. Ann. N Y Acad. Sci. 1971, 183:369-374.
34. Giaccone G. Treatment of thymoma and thymic carcinoma. Ann. Oncol. 2000, 11(Suppl 3):245-246.
35. Graeber G.M., Tamim W. Current status of the diagnosis and treatment of thymoma. Semin. Thorac. Cardiovasc. Surg. 2000, 12:268-277.
36. Grob D. Natural history of myasthenia gravis. Myasthenia Gravis and Myasthenic Disorders 1999, 131-145. Oxford University Press, Oxford, UK. A.G. Engel (Ed.).
37. Grob D., Simpson D., Mitsumoto H., Hoch B., Mokhatarian F., Bender A., Greenberg M., Koo A., Nakayama S. Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 1995, 45:338-344.
38. Gronseth G.S., Barohn R.J. Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55:7-15.
39. Harper C.M. Electrodiagnosis of end plat disease. Myasthenia Gravis and Myasthenic Disorders 2001, 65-84. Oxford University Press, Oxford, UK. A.G. Engel (Ed.).
40. Hauser R.A., Malek A.R., Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998, 51:912-913.
41. Hejna M., Haberl I., Raderer M. Nonsurgical management of malignant thymoma. Cancer 1999, 85:1871-1884.
42. Herrlinger U., Weller M., Dichgans J., Melms A. Association of primary central nervous system lymphoma with longterm azathioprine therapy for myasthenia gravis. Ann. Neurol. 2000, 47:682-683.
43. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Med. 2001, 7:365-368.
44. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 1997, 120:865-916.
45. Hohlfeld R., Michels M., Heininger K., Besinger U., Toyka K.V. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 1988, 38:258-261.
46. Hohlfeld R., Toyka K.V., Besinger U.A., Gerhold B., Heininger K. Myasthenia gravis: Reactivation of clinical disease and of autoimmune factors after discontinuation of longterm azathioprine. Ann. Neurol. 1985, 17:238-242.
47. Hohfeld R., Wekerle H. The immunopathogenesis of myasthenia gravis. Myasthenia Gravis and Myasthenic Syndromes 1999, 87-110. Oxford University Press, Oxford, UK. A.G. Engel (Ed.).
48. Howard F.M., Duane D.D., Lambert E.H., Daube J.R. Alternate-day prednisone: preliminary report of a doubleblind controlled study. Ann. N Y Acad. Sci. 1976, 274:596-607.
49. Howard J.F. Adverse drug effects on neuromuscular transmission. Semin. Neurol. 1990, 10:89-102.
50. Howard J.F. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis. Neurology 1998, 51:S30-S36.
51. Jaretzki A., Barohn R.J., Ernstoff R.M., Kaminski H.J., Keesey J.C., Penn A.S., Sanders D.B., Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America Myasthenia gravis: Recommendations for clinical research standards. Neurology 2000, 55:16-23.
52. Katz B. Glucocorticoids in relation to inflammatory disease. Cecil Textbook of Medicine 2000, 111-114. W.B. Saunders, Philadelphia. L. Goldman, J.C. Bennett (Eds.).
53. Kennel P.F., Vilquin J.-T., Braun S., Fonteneau P., Warter J.-M., Poindron P. Myasthenia gravis: Comparative autoantibody assays using human muscle, TE671, and glucocortiicoidtreated TE671 cells as sources of antigen. Clin. Immunol. Immunopathol. 1995, 74:293-296.
54. Kiani A., Rao A., Aramburu J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 2000, 12:359-372.
55. Krucylak P.E., Naunheim K.S. Preoperative preparation and anesthetic management of patients with myasthenia gravis. Semin. Thorac. Cardiovasc. Surg. 1999, 11:47-53.
56. Kuks J.B., Djojoatmodjo S., Oosterhuis H.J. Azathioprine in myasthetnia gravis: observations in 41 patients and a review of literature. Neuromuscul. Disord. 1991, 1:423-431.
57. Kupersmith M.J., Moster M., Bhuiyan S., Warren F., Weinberg H. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch. Neurol. 1996, 53:802-804.
58. Lara P.N. Malignant thymoma: current status and future directions. Cancer Treat. Rev. 2000, 26:127-131.
59. Lindberg C., Andersen O., Lefvert A.K. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol. Scand. 1998, 97:370-373.
60. Lindner A., Schalke B., Toyka K.V. Outcome in juvenile-onset myasthenia gravis: a retrospective study with longterm follow-up of 79 patients. J. Neurol. 1997, 244:515-520.
61. Lipsky J.J. Mycophenolate mofetil. Lancet. 1996, 348:1357-1359.
62. Loehrer P.J. Current approaches to the treatment of thymoma. Ann. Med. 1999, 31(Suppl 2):73-79.
63. MacDonald B.K., Cockerell O.C., Sander J.W., Shorvon S.D. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000, 123(Pt 4):665-676.
64. Masaoka A., Monden Y., Nakahara K., Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981, 48:2485-2492.
65. Matell G., Bergstrom K., Franksson C., Hammarstrom L., Lefvert A.K., Moller E., von Reis G., Smith E. Effects of some immunosuppressive procedures on myasthenia gravis. Ann. N Y Acad. Sci. 1976, 274:659-676.
66. McEvoy K.M., Windebank A.J., Daube J.R., Low P.A. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N. Engl. J. Med. 1989, 321:1567-1571.
67. Meiner Z., Ben Hur T., River Y., Reches A. Aseptic meningitis as complication of intravenous immunoglobulin therapy for myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 1993, 56:830-831.
68. Meriggioli M.N., Rowin J. Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Muscle Nerve 2000, 23:1287-1289.
69. Mertens H.G., Balzereit F., Leipert M. The treatment of severe myasthenia gravis with immunosuppressive agents. Eur. Neurol. 1969, 2:321-339.
70. Mertens H.G., Hertel G., Reuther P., Ricker K. Effect of immunosuppressive drugs (azathioprine). Ann. N Y Acad. Sci. 1981, 377:691-699.
71. Michels M., Hohlfeld R., Hartung H.P., Heininger K., Besinger U.A., Toyka K.V. Myasthenia gravis: discontinuation of long-term azathioprine. Ann. Neurol. 1988, 24:798.
72. Millard C.B., Broomfield C.A. Anticholinesterases: medical applications of neurochemical principles. J. Neurochem. 1995, 64:1909-1918.
73. Muller-Hermelink H.K., Marx A. Thymoma. Curr. Opin. Oncol. 2000, 12:426-433.
74. A randomized clincial trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. J. Neurol. Neurosurg. Psychiatry 1993, 56:1157-1163. Myasthenia Gravis Clinical Study Group.
75. Newsom-Davis J., Lang B. The Lambert-Eaton syndrome. Myasthenia Gracis and Myasthenic Syndromes 1999, 205-228. Oxford University Press, Oxford, UK. A.G. Engel (Ed.).
76. Nordenbo A.M., Somnier F.E. Acute deterioration of myasthenia gravis after intravenous administration of gadolinium-DTPA. Lancet 1992, 340:1168.
77. Oosterhuis H.J.G.H. The natural course of myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 1989, 52:1121-1127.
78. Palace J., Newson-Davis J., Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998, 50:1778-1783. The Myasthenia Gravis Study Group.
79. Papazian O. Transient neonatal myasthenia gravis. J. Child. Neurol. 1992, 7:135-141.
80. Perez M.C., Buot W.L., Mercado-Danguilan C., Bagabaldo Z.G., Renales L.D. Stable remissions in myasthenia gravis. Neurology 1981, 31:32-37.
81. Plauche W.C. Myasthenia gravis in mothers and their newborns. Clin. Obstet. Gynecol. 1991, 34:82-99.
82. Qureshi A.I., Choudhry M.A., Akbar M.S., Mohammad Y., Chua H.C., Yahia A.M., Ulatowski J.A., Krendel D.A., Leshner R.T. Plasma exchange versus immunoglobulin treatment in myasthenic crisis. Neurology 1999, 52:629-632.
83. Romi F., Skeje G.O., Aarli J.A., Gilhus N.E. Muscle autoantibodies in subgroups of myasthenia gravis patients. J. Neurol. 2000, 247:369-375.
84. Samuelsson A., Towers T.L., Ravetch J.V. Antiinflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
85. Sato T., Ishigaki Y., Komiya T., Tsuda H. Therapeutic immunoadsorption of acetylcholine receptor antibodies in myasthenia gravis. Ann. N Y Acad. Sci. 1988, 540:554-556.
86. Schumm F., Wietholter H., Fateh-Moghadam A., Dichgans J. Thymectomy in myasthenia with pure ocular symptoms. J. Neurol. Neurosurg. Psychiatry 1985, 48:332-337.
87. Selcen D., Dabrowski E.R., Michon A.M., Nigro M.A. High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis. Pediatr. Neurol. 2000, 22:40-43.
88. Seybold M.E. Thymectomy in childhood myasthenia gravis. Ann. N Y Acad. Sci. 1998, 841:731-741.
89. Seybold M.E. Treatment of myasthenia gravis. Myasthenia Gravis and Myasthenic Disorders 1999, 167-201. Oxford University Press, Oxford, UK. A.G. Engel (Ed.).
90. Shibuya N., Sato T., Osame M., Takegami T., Doi S., Kawanami S. Immunoadsorption therapy for myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 1994, 57:578-581.
91. Somnier F.E. Anti-acetylcholine receptor (AChR) antibodies measurement in myasthenia gravis: The use of cell line TE67 as a source of AChR antigen. J. Neuroimmunol. 1994, 51:63-68.
92. Steg R.E., Lefkowitz D.M. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 1994, 44:1180-1181.
93. Tagher R.J., Baumann R., Desai N. Failure of intravenously administered immunoglobulin in the treatment of neonatal myasthenia gravis. J. Pediatr. 1999, 134:233-235.
94. Tandan R., Taylor R., DiCostanzo D.P., Sharma K., Fries T., Roberts J. Metastasizing thymoma and myasthenia gravis. Favorable response to glucocorticoids after failed chemotherapy and radiation therapy. Cancer 1990, 65:1286-1290.
95. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, Jaretzki A., Barohn R.J., Ernstorff R.M., Kaminski H.J., Keesey J.C., Penn A.S., Sanders D.B. Myasthenia gravis. Recommendations for clinical research standards. Neurology 2000, 55:16-23.
96. Thomas C.R., Wright C.D., Loehrer P.J. Thymoma: state of the art. J. Clin. Oncol. 1999, 17:2280-2289.
97. Tindall R.S., Phillips J.T., Rollins J.A., Wells L., Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann. N Y Acad. Sci. 1993, 681:539-551.
98. Tindall R.S., Rollins J.A., Phillips J.T., Greenlee R.G., Wells L., Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N. Engl. J. Med. 1987, 316:719-724.
99. Vincent A., Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles. Clin. Exp. Immunol. 1982, 49:257-265.
100. Voltz R., Hohlfeld R., Fateh-Moghadam A., Witt T.N., Wick M., Reimers C., Siegele B., Wekerle H. Myasthenia gravis: Measurement of anti-AChR autoantibodies using cell line TE671. Neurology 1991, 41:1836-1838.
101. Willcox N., Schluep M., Ritter M.A., Newsom-Davis J. The thymus in seronegative myasthenia gravis patients. J. Neurol. 1991, 238:256-261.
102. Witte A.S., Cornblath D.R., Parry G.J., Lisak R.P., Schatz N.J. Azathioprine in the treatment of myasthenia gravis. Ann. Neurol. 1984, 15:602-605.
103. Wu J.M., Wu B., Guarnieri F., August J.T., Drachman D.B. Targeting antigen-specific T cells by genetically engineered antigen presenting cells. A strategy for specific immunotherapy of autoimmune disease. J. Neuroimmunol. 2000, 106:145-153.
104. Yeh J.H., Chiu H.C. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J. Neurol. 2000, 247:510-513.